FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Abstract Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46)...

Full description

Bibliographic Details
Main Authors: Andrea Gombos, David Venet, Lieveke Ameye, Peter Vuylsteke, Patrick Neven, Vincent Richard, Francois P. Duhoux, Jean-Francois Laes, Françoise Rothe, Christos Sotiriou, Marianne Paesmans, Ahmad Awada, Thomas Guiot, Patrick Flamen, Martine Piccart-Gebhart, Michail Ignatiadis, Géraldine Gebhart
Format: Article
Language:English
Published: Nature Portfolio 2021-09-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00331-8

Internet

https://doi.org/10.1038/s41523-021-00331-8

Similar Items